Literature DB >> 21940914

Effectiveness of the targeted hepatitis B vaccination program in Greenland.

Malene L Børresen1, Anders Koch, Robert J Biggar, Karin Ladefoged, Mads Melbye, Jan Wohlfahrt, Tyra Grove Krause.   

Abstract

OBJECTIVES: To evaluate the effectiveness of the hepatitis B virus (HBV) vaccination program in Greenland, which targets children born to mothers who are positive for HBV surface antigen (HBsAg), we determined vaccination coverage, levels of postvaccination antibodies, and frequency of breakthrough infections in at-risk children.
METHODS: We conducted a population-based retrospective cohort study with data from nationwide registries. We identified all children born to HBsAg-positive mothers from 1992 to 2007 and collected data on their HBV vaccination status. In 2008 to 2010, we tested the children for HBV core antibody, HBsAg, and anti-HBsAg antibody (HBsAb).
RESULTS: Of 4050 pregnant women, 3.2% were HBsAg positive. Of 207 children born to these women, 20% received no vaccinations, and only 58% received at least 3 vaccinations. At follow-up, HBsAb levels in vaccinated children were much lower than expected, and 8 (6%) of 140 at-risk children had breakthrough infections, with 4 chronically infected (persistently HBsAg positive).
CONCLUSIONS: The prevention program targeting children at risk for HBV in Greenland is ineffective. HBV vaccination should be included in the universal childhood vaccination program, and postvaccination HBsAb levels should be monitored.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21940914      PMCID: PMC3483978          DOI: 10.2105/AJPH.2011.300239

Source DB:  PubMed          Journal:  Am J Public Health        ISSN: 0090-0036            Impact factor:   9.308


  34 in total

1.  A population-based register study of vaccine coverage among children in Greenland.

Authors:  Christoffer Holst Hansen; Anders Koch; Jan Wohlfahrt; Mads Melbye
Journal:  Vaccine       Date:  2003-04-02       Impact factor: 3.641

Review 2.  Mutations of the surface protein of hepatitis B virus.

Authors:  Jane N Zuckerman; Arie J Zuckerman
Journal:  Antiviral Res       Date:  2003-10       Impact factor: 5.970

3.  Frequency of atopy in the Arctic in 1987 and 1998.

Authors:  Tyra Krause; Anders Koch; Jeppe Friborg; Lars K Poulsen; Bjarne Kristensen; Mads Melbye
Journal:  Lancet       Date:  2002-08-31       Impact factor: 79.321

4.  Hepatitis and hepatitis B-antigen in Greenland.

Authors:  P Skinhoj; A McNair; S T Andersen
Journal:  Am J Epidemiol       Date:  1974-01       Impact factor: 4.897

5.  Atopic sensitization among children in an arctic environment.

Authors:  T G Krause; A Koch; L K Poulsen; B Kristensen; O R Olsen; M Melbye
Journal:  Clin Exp Allergy       Date:  2002-03       Impact factor: 5.018

6.  Hepatitis and hepatitis B-antigen in Greenland. II: Occurrence and interrelation of hepatitis B associated surface, core, and "e" antigen-antibody systems in a highly endemic area.

Authors:  P Skinhoj
Journal:  Am J Epidemiol       Date:  1977-02       Impact factor: 4.897

7.  Cancer in Greenlandic Inuit 1973-1997: a cohort study.

Authors:  Jeppe Friborg; Anders Koch; Jan Wohlfarht; Hans-Henrik Storm; Mads Melbye
Journal:  Int J Cancer       Date:  2003-12-20       Impact factor: 7.396

8.  Occurrence of cirrhosis and primary liver cancer in an Eskimo population hyperendemically infected with hepatitis B virus.

Authors:  P Skinhøj; J P Hart Hansen; N H Nielsen; F Mikkelsen
Journal:  Am J Epidemiol       Date:  1978-08       Impact factor: 4.897

9.  Hepatitis B vaccine freezing in the Indonesian cold chain: evidence and solutions.

Authors:  Carib M Nelson; Hariadi Wibisono; Hary Purwanto; Isa Mansyur; Vanda Moniaga; Anton Widjaya
Journal:  Bull World Health Organ       Date:  2004-03-16       Impact factor: 9.408

10.  Cost-effectiveness of hepatitis-B vaccine in Greece. A country of intermediate HBV endemicity.

Authors:  E J Hatziandreu; A Hatzakis; S Hatziyannis; M A Kane; M C Weinstein
Journal:  Int J Technol Assess Health Care       Date:  1991       Impact factor: 2.188

View more
  7 in total

1.  Hepatitis B virus infection among pregnant women in Haiti: A cross-sectional serosurvey.

Authors:  Rania A Tohme; Jocelyne Andre-Alboth; Alexandra Tejada-Strop; Ran Shi; Jacques Boncy; Jeannot François; Jean Wysler Domercant; Mark Griswold; Erlantz Hyppolite; Paul Adrien; Saleem Kamili
Journal:  J Clin Virol       Date:  2016-01-28       Impact factor: 3.168

Review 2.  Hepatitis B virus: where do we stand and what is the next step for eradication?

Authors:  Haruki Komatsu
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

3.  Selective Hepatitis B Birth-Dose Vaccination in São Tomé and Príncipe: A Program Assessment and Cost-Effectiveness Study.

Authors:  José E Hagan; Elizabeth Carvalho; Vladimir Souza; Maria Queresma Dos Anjos; Taiwo O Abimbola; Sarah W Pallas; M Carole Tevi Benissan; Stephanie Shendale; Karen Hennessey; Minal K Patel
Journal:  Am J Trop Med Hyg       Date:  2019-10       Impact factor: 2.345

Review 4.  The status of hepatitis B control in the African region.

Authors:  Lucy Breakwell; Carol Tevi-Benissan; Lana Childs; Richard Mihigo; Rania Tohme
Journal:  Pan Afr Med J       Date:  2017-06-22

5.  Implementing a Birth Dose of Hepatitis B Vaccine in Africa: Findings from Assessments in 5 Countries.

Authors:  Edna Moturi; Carole Tevi-Benissan; José E Hagan; Stephanie Shendale; David Mayenga; Daniel Murokora; Minal Patel; Karen Hennessey; Richard Mihigo
Journal:  J Immunol Sci       Date:  2018-07-02

6.  The Arctic Human Health Initiative: a legacy of the International Polar Year 2007-2009.

Authors:  Alan J Parkinson
Journal:  Int J Circumpolar Health       Date:  2013-08-05       Impact factor: 1.228

7.  Burden and prevention of viral hepatitis in the Arctic region, Copenhagen, Denmark, 22-23 March 2012.

Authors:  David FitzSimons; Brian McMahon; Greet Hendrickx; Alex Vorsters; Pierre Van Damme
Journal:  Int J Circumpolar Health       Date:  2013-07-17       Impact factor: 1.228

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.